Teladoc Health, Inc. (NYSE:TDOC) Insider Sells $31,395.98 in Stock

Teladoc Health, Inc. (NYSE:TDOC) insider Vidya Raman-Tangella sold 3,857 shares of the business’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total transaction of $31,395.98. Following the completion of the transaction, the insider now owns 33,667 shares of the company’s stock, valued at approximately $274,049.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Vidya Raman-Tangella also recently made the following trade(s):

• On Monday, June 3rd, Vidya Raman-Tangella sold 1,122 shares of Teladoc Health stock. The stock was sold at an average price of $11.16, for a total transaction of $12,521.52.

Teladoc Health Trading Down 4.3 %

Teladoc Health stock traded down $0.34 during trading hours on Monday, hitting $7.61. The stock had a trading volume of 8,635,004 shares, compared to its average volume of 5,484,486. Teladoc Health, Inc. has a one year low of $7.31 and a one year high of $26.00. The company has a quick ratio of 3.74, a current ratio of 3.82 and a debt-to-equity ratio of 0.67. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -5.64 and a beta of 0.93. The business’s 50 day simple moving average is $9.88 and its 200-day simple moving average is $13.61.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on TDOC shares. Deutsche Bank Aktiengesellschaft cut their price target on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating on the stock in a report on Friday. Canaccord Genuity Group decreased their price objective on shares of Teladoc Health from $25.00 to $17.00 and set a “buy” rating on the stock in a report on Thursday. Bank of America reduced their price objective on shares of Teladoc Health from $16.50 to $13.50 and set a “neutral” rating on the stock in a research note on Tuesday, May 14th. Stifel Nicolaus dropped their target price on shares of Teladoc Health from $16.00 to $9.00 and set a “hold” rating on the stock in a report on Thursday. Finally, Barclays reduced their price objective on shares of Teladoc Health from $20.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday. Fourteen analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $14.44.

Institutional Trading of Teladoc Health

Several hedge funds have recently made changes to their positions in TDOC. ICA Group Wealth Management LLC bought a new stake in Teladoc Health during the fourth quarter valued at about $28,000. Hexagon Capital Partners LLC grew its position in shares of Teladoc Health by 204.4% during the 4th quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock valued at $34,000 after acquiring an additional 1,065 shares during the period. RIA Advisory Group LLC purchased a new position in Teladoc Health in the 4th quarter worth approximately $36,000. GAMMA Investing LLC acquired a new stake in Teladoc Health in the 4th quarter valued at approximately $41,000. Finally, Principal Securities Inc. acquired a new position in shares of Teladoc Health in the fourth quarter worth $45,000. 76.82% of the stock is currently owned by institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.